Amgen (AMGN) Announces Erenumab Phase 2 Met Primary Endpoint in Chronic Migraine Prevention
Tweet Send to a Friend
Amgen (Nasdaq: AMGN) announced positive top-line results from the global Phase 2 study evaluating the efficacy and safety of erenumab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
